TABLE 1.

Baseline Clinical, Immune, and Viral Characteristics of the Study Group

VariablePatients
AllVS/ISVF/ISVF/IF
n4018175
Age, y*7.16.95.79.5
Gender
    Male2410131
    Female16844
Race
    Black2713113
    White10352
    Hispanic2200
    Asian1010
Mode of infection
    Sexual1001
    Vertical3416144
    Blood products5230
Treatment
    Indinavir9342
    NFV131030
    RTV185103
Immune stage
    211920
    3299155
CD4%* (25th–75th quartile)13 (3–28)24 (11–32)8 (3–18)1 (1–7)
CD4 T cells per μL* (25th–75th quartile)256 (45–733)672 (265–903)205 (33–407)25 (5.7–57)
Log10 viral RNA copies per mL* (25th–75th quartile)5.1 (4.2–5.5)4.3 (4.0–5.4)5.1 (4.4–5.6)5.4 (5.3–5.5)
Disease stage
    A10640
    B14860
    C16475
  • * Median.

  • P values: .12 for age, .07 for gender, .54 for ethnicity, and .09 for mode of infection (χ2).

  • P value: .014 between NFV and non-NFV (χ2).